These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
189 related items for PubMed ID: 35120800
1. The role of androgens in transgender medicine. Dimakopoulou A, Millar OD, Moschonas D, Jayasena CN. Best Pract Res Clin Endocrinol Metab; 2022 Sep; 36(5):101617. PubMed ID: 35120800 [Abstract] [Full Text] [Related]
2. Changes in hormonal and metabolic parameters in transgender subjects on cross-sex hormone therapy: A cohort study. Vita R, Settineri S, Liotta M, Benvenga S, Trimarchi F. Maturitas; 2018 Jan; 107():92-96. PubMed ID: 29169588 [Abstract] [Full Text] [Related]
3. Masculinizing hormone therapy effect on breast tissue: Changes in estrogen and androgen receptors in transgender female-to-male mastectomies. Chaum M, Grossi S, Chen J, Hu V, Ray E, Giuliano A, Bose S. Breast; 2023 Dec; 72():103596. PubMed ID: 37951051 [Abstract] [Full Text] [Related]
4. Hormone therapy in female-to-male transgender patients: searching for a lifelong balance. Schönauer LM, Dellino M, Loverro M, Carriero C, Capursi T, Leoni C, Loverro G, Di Naro E. Hormones (Athens); 2021 Mar; 20(1):151-159. PubMed ID: 33026609 [Abstract] [Full Text] [Related]
5. Testosterone and other treatments for transgender males and non-binary trans masculine individuals. Dimakopoulou A, Seal LJ. Best Pract Res Clin Endocrinol Metab; 2024 Sep; 38(5):101908. PubMed ID: 38997938 [Abstract] [Full Text] [Related]
6. Ovarian, breast, and metabolic changes induced by androgen treatment in transgender men. Pirtea P, Ayoubi JM, Desmedt S, T'Sjoen G. Fertil Steril; 2021 Oct; 116(4):936-942. PubMed ID: 34481638 [Abstract] [Full Text] [Related]
7. Physical changes, laboratory parameters, and bone mineral density during testosterone treatment in adolescents with gender dysphoria. Stoffers IE, de Vries MC, Hannema SE. J Sex Med; 2019 Sep; 16(9):1459-1468. PubMed ID: 31405768 [Abstract] [Full Text] [Related]
8. Effects of 12 Months' Treatment with Testosterone Undecanoate on Markers for Erythropoietic Activity and Safety Aspects in Transgender and Cisgender Hypogonadal Men. Lethin K, Aardal E, Lood Y, Ekman B, Wahlberg J. J Appl Lab Med; 2024 Mar 01; 9(2):223-236. PubMed ID: 38085088 [Abstract] [Full Text] [Related]
11. Female-to-male patients have high prevalence of unsatisfactory Paps compared to non-transgender females: implications for cervical cancer screening. Peitzmeier SM, Reisner SL, Harigopal P, Potter J. J Gen Intern Med; 2014 May 01; 29(5):778-84. PubMed ID: 24424775 [Abstract] [Full Text] [Related]
13. THE BIOLOGIC BASIS OF TRANSGENDER IDENTITY: 2D:4D FINGER LENGTH RATIOS IMPLICATE A ROLE FOR PRENATAL ANDROGEN ACTIVITY. Leinung M, Wu C. Endocr Pract; 2017 Jun 01; 23(6):669-671. PubMed ID: 28332875 [Abstract] [Full Text] [Related]
16. Implications for management of ovarian cancer in a transgender man: Impact of androgens and androgen receptor status. Aubrey C, Saad N, Köbel M, Mattatall F, Nelson G, Glaze S. Gynecol Oncol; 2021 May 01; 161(2):342-346. PubMed ID: 33663874 [Abstract] [Full Text] [Related]